Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 20/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.88 |
| ▸ | PLK2 | Q9NYY3 | 6/20 | 0.88 |
| ▸ | FLT3 | P36888 | 5/20 | 0.88 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.88 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.88 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.88 |
| ▸ | MELK | Q14680 | 1/20 | 0.88 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.88 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.87 |
| ▸ | CDK2 | P24941 | 3/20 | 0.87 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.87 |
| ▸ | NEK6 | Q9HC98 | 3/20 | 0.85 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onvansertib SCHEMBL1228019 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| Onvansertib SCHEMBL29379736 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3503742 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3504256 | 0.93 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL13225440 | 0.92 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL25627189 | 0.92 | PLK1 (0.86) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3503253 | 0.92 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| Hydrochloric Acid SCHEMBL3504656 | 0.92 | PLK1 (0.99) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL25623877 | 0.91 | PLK1 (0.85) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3503601 | 0.90 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125822-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-11-19 | — | — | EP | claimed |
| US-8614220-B2 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-24 | — | — | US | claimed |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2010-08-26 | — | — | US | claimed |
| EP-2125822-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-12-02 | — | — | EP | claimed |
| WO-2008074788-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | claimed |
| EP-2125822-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-11-19 | — | — | EP | disclosed |
| US-8614220-B2 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-24 | — | — | US | disclosed |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2010-08-26 | — | — | US | disclosed |
| EP-2125822-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008074788-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | PLK1 91/4885PLK3 121/4885PLK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.